Needham & Company LLC Reaffirms “Buy” Rating for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE:BSX)‘s stock had its “buy” rating reissued by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $97.00 price target on the medical equipment provider’s stock. Needham & Company LLC’s price target indicates a potential upside of 39.49% from the company’s current price.

Other equities research analysts have also issued reports about the stock. Citigroup cut their target price on shares of Boston Scientific from $102.00 to $94.00 and set a “buy” rating on the stock in a report on Wednesday, March 11th. BTIG Research reissued a “buy” rating on shares of Boston Scientific in a report on Wednesday, February 4th. The Goldman Sachs Group set a $99.00 price objective on shares of Boston Scientific in a research report on Thursday, February 5th. Evercore dropped their price objective on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Finally, Weiss Ratings lowered Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, February 4th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $106.27.

Boston Scientific Price Performance

Boston Scientific stock opened at $69.54 on Friday. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $103.34 billion, a P/E ratio of 35.84, a PEG ratio of 0.97 and a beta of 0.69. The business has a 50-day moving average of $79.74 and a 200-day moving average of $92.05. Boston Scientific has a 1 year low of $67.56 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same period last year, the company posted $0.70 EPS. Boston Scientific’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities analysts anticipate that Boston Scientific will post 2.85 EPS for the current year.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BSX. Vanguard Group Inc. raised its stake in shares of Boston Scientific by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after purchasing an additional 1,436,550 shares during the period. State Street Corp lifted its holdings in shares of Boston Scientific by 1.4% in the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after purchasing an additional 920,495 shares in the last quarter. Capital World Investors boosted its position in shares of Boston Scientific by 1.9% during the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after buying an additional 502,627 shares during the period. Norges Bank bought a new position in shares of Boston Scientific during the fourth quarter worth about $2,199,395,000. Finally, Morgan Stanley grew its holdings in shares of Boston Scientific by 10.8% during the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after buying an additional 2,246,308 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Needham/analyst support — Needham & Company maintained a Buy rating and $97 price target, arguing the financial fallout from the Accolade pacemaker recalls is limited and supports a continued Buy stance. Boston Scientific: Limited Financial Fallout From Pacemaker Recalls Supports Continued Buy Rating
• Neutral Sentiment: Stifel trims target but keeps Buy — Stifel cut its price target from $110 to $90 while retaining a Buy rating, reducing upside expectations even as the firm remains constructive. Benzinga: Stifel Nicolaus Price Target
• Neutral Sentiment: Other firms lower expectations — Truist and UBS have lowered price targets/expectations (Truist to $92), signaling more cautious analyst views on near-term growth despite mixed analyst conviction. Truist Lowers Boston Scientific Price Target to $92
• Negative Sentiment: Multiple securities class-action alerts — Several law firms have filed or are soliciting lead plaintiffs for securities fraud suits tied to disclosures covering July 2025–Feb 2026; reminders and deadlines (May 4, 2026) are fueling legal uncertainty and potential future liability. Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: NYT report alleges long-standing battery issues — The New York Times reports Boston Scientific was aware of pacemaker battery problems for years, a story that raises reputational and regulatory risk beyond the company’s stated scope. Boston Scientific Knew of Pacemaker Battery Problems for Years
• Negative Sentiment: Recall expanded — Market chatter notes Boston Scientific amended its Accolade pacemaker recall, increasing the affected population to ~1.6 million devices, which raises potential remediation costs and investor concern. Market Chatter: Boston Scientific Amends Recall of Accolade Pacemakers, Affected Population Now 1.6 Million
• Negative Sentiment: High-profile criticism — Jim Cramer publicly criticized BSX’s recent performance and competitive pressures, a sentiment that can influence retail flows and short-term sentiment. Jim Cramer on Boston Scientific: “This Stock Was One of the Greatest Performers, It’s Not Anymore”

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.